Format

Send to

Choose Destination
Trends Microbiol. 2015 Aug;23(8):445-7. doi: 10.1016/j.tim.2015.05.001.

Improving preclinical models of HIV microbicide efficacy.

Author information

1
Department of Urology, University of California, San Francisco, San Francisco, CA 94158, USA; Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA.
2
Institute of Molecular Virology, UPEP, Ulm University Medical Centre, Meyerhofstrasse 1, 89081 Ulm, Germany; Ulm Peptide Pharmaceuticals, Ulm University, Albert-Einstein-Allee 11, 89081 Ulm, Germany. Electronic address: jan.muench@uni-ulm.de.

Abstract

Despite potent in vitro efficacy, most topical microbicides fail to effectively prevent HIV transmission. One reason for clinical failure may be that current microbicide testing does not reflect the environment encountered during sexual virus transmission. We discuss how preclinical microbicide development could be improved by more closely mimicking real-life conditions.

KEYWORDS:

HIV-1; amyloids; microbicide; semen; transmission; vaginal fluid

PMID:
26250616
PMCID:
PMC4818646
DOI:
10.1016/j.tim.2015.05.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center